Corvus Pharmaceuticals, Inc. — Director's Dealing 2019

Jan 30, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2019-01-28

Reporting Person: Grais Linda S (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-28	Stock Option (Right to Buy)	$3.88	A	30000	Acquired	2029-01-28	Common Stock (30000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from January 28, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.